{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:03:52Z","timestamp":1794647032986,"version":"4.9.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gesynta Pharma AB"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Our objective was to test the hypothesis, in a double-blind, placebo-controlled study that vipoglanstat, an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), which decreases prostaglandin E2 (PGE2) and increases prostacyclin biosynthesis, improves RP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with SSc and \u22657 RP attacks during the last screening week prior to a baseline visit were randomized to 4\u2009weeks treatment with vipoglanstat 120\u2009mg or placebo. A daily electronic diary captured RP attacks (duration and pain) and Raynaud\u2019s Condition Score, with change in RP attacks\/week as the primary end point. Cold challenge assessments were performed at baseline and end of treatment. Exploratory end points included patients\u2019 and physicians\u2019 global impression of change, Assessment of Scleroderma-associated Raynaud\u2019s Phenomenon questionnaire, mPGES-1 activity, and urinary excretion of arachidonic acid metabolites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-nine subjects received vipoglanstat (n\u2009=\u200933) or placebo (n\u2009=\u200936). The mean weekly number of RP attacks [baseline; vipoglanstat 14.4 (S.D. 6.7), placebo 18.2 (12.6)] decreased by 3.4 (95% CI \u20135.8; \u20131.0) and 4.2 (\u20136.5; \u20132.0) attacks per week (P\u2009=\u20090.628), respectively. All patient-reported outcomes improved, with no difference between the groups. The mean change in recovery of peripheral blood flow after the cold challenge did not differ between the study groups. Vipoglanstat fully inhibited mPGES-1, resulting in 57% reduction of PGE2 and 50% increase of prostacyclin metabolites in the urine. Vipoglanstat was safe and well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although vipoglanstat was safe, and well tolerated in a dose achieving full inhibition of mPGES-1, it was ineffective in SSc-related RP. Further development and evaluation of vipoglanstat will therefore be in other diseases where mPGES-1 plays a pathogenetic role.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, https:\/\/www.clinicaltrials.gov, NCT0474420.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae049","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T08:10:16Z","timestamp":1706688616000},"page":"704-713","source":"Crossref","is-referenced-by-count":15,"title":["A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's"],"prefix":"10.1093","volume":"64","author":[{"given":"G\u00f6ran","family":"Tornling","sequence":"first","affiliation":[{"name":"Respiratory Medicine Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Gesynta Pharma AB , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Edenius","sequence":"additional","affiliation":[{"name":"Gesynta Pharma AB , Stockholm,","place":["Sweden"]},{"name":"Rheumatology Division, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Pauling","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Bristol NHS Trust , Bristol,","place":["UK"]},{"name":"Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol , Bristol,","place":["UK"]},{"name":"Royal National Hospital for Rheumatic Diseases (part of the Royal United Hospitals NHS Foundation Trust) , Bath,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Royal Free Hospital and University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Olsson","sequence":"additional","affiliation":[{"name":"Gesynta Pharma AB , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kowalski","sequence":"additional","affiliation":[{"name":"JK Biostatistics AB , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-2882","authenticated-orcid":false,"given":"Andrea","family":"Murray","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Anderson","sequence":"additional","affiliation":[{"name":"Aintree University Hospital, Liverpool University Hospitals NHS Trust , Liverpool,","place":["UK"]},{"name":"Lancaster Medical School, Lancaster University , Lancaster,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Bhat","sequence":"additional","affiliation":[{"name":"Ninewells Hospital and Medical School , Dundee,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatology & Musculoskeletal Medicine, and NIHR Leeds Biomedical Research Centre, University of Leeds , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Hall","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Korkosz","sequence":"additional","affiliation":[{"name":"Centrum Medyczne Pratia MCM Krakow , Krakow,","place":["Poland"]},{"name":"Jagiellonian University Medical College , Krakow,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Krasowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Olas","sequence":"additional","affiliation":[{"name":"Ma\u0142opolskie Centrum Kliniczne , Krak\u00f3w,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-7945","authenticated-orcid":false,"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ghent University , Ghent,","place":["Belgium"]},{"name":"Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC) , Ghent,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5544-5785","authenticated-orcid":false,"given":"Jacob M","family":"van Laar","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon C","family":"Vonk","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wojteczek","sequence":"additional","affiliation":[{"name":"Early Phase Clinical Trials Centre, Medical University of Gda\u0144sk , Gda\u0144sk,","place":["Poland"]},{"name":"Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gda\u0144sk , Gda\u0144sk,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-7926","authenticated-orcid":false,"given":"Ariane L","family":"Herrick","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2025032905211428500_keae049-B1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025032905211428500_keae049-B2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","article-title":"Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey","volume":"46","author":"Frantz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025032905211428500_keae049-B3","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"2025032905211428500_keae049-B4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025032905211428500_keae049-B5","first-page":"CD000953","article-title":"Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis","volume":"1998","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2025032905211428500_keae049-B6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/03009742.2021.1907926","article-title":"Temperature response to cold challenge and mobile phone thermography as outcome measures for systemic sclerosis-related Raynaud's phenomenon","volume":"50","author":"Herrick","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2025032905211428500_keae049-B7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5301\/jsrd.5000232","article-title":"Digital ulcers in SSc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up","volume":"2","author":"Seibold","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2025032905211428500_keae049-B8","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: a Randomized, Placebo-Controlled, Phase II Study","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025032905211428500_keae049-B9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.prostaglandins.2013.09.001","article-title":"Characterization of a human and murine mPGES-1 inhibitor and comparison to mPGES-1 genetic deletion in mouse models of inflammation","volume":"107","author":"Leclerc","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2025032905211428500_keae049-B10","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/cvr\/cvz290","article-title":"Mechanistic definition of the cardiovascular mPGES-1\/COX-2\/ADMA axis","volume":"116","author":"Kirkby","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2025032905211428500_keae049-B11","doi-asserted-by":"crossref","first-page":"14507","DOI":"10.1073\/pnas.0606586103","article-title":"Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis","volume":"103","author":"Wang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025032905211428500_keae049-B12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/annrheumdis-2020-eular.5503","article-title":"Inhibition of microsomal prostaglandin E synthase-1 (mPGES-1) by GS-248 reduces prostaglandin E2 biosynthesis while increasing prostacyclin in human subjects","volume":"79","author":"Edenius","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025032905211428500_keae049-B13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/cpt.260","article-title":"Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib","volume":"99","author":"Jin","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2025032905211428500_keae049-B14","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025032905211428500_keae049-B15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/art.40457","article-title":"A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud's phenomenon","volume":"70","author":"Wilkinson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025032905211428500_keae049-B16","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/acr.25038","article-title":"Assessment of the systemic sclerosis-associated Raynaud's Phenomenon questionnaire: item bank and short-form development","volume":"75","author":"Yu","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025032905211428500_keae049-B17","doi-asserted-by":"publisher","first-page":"kead371","DOI":"10.1093\/rheumatology\/kead371","article-title":"Construct validity and reliability of the assessment of systemic sclerosis-associated Raynaud's phenomenon (ASRAP) questionnaire","author":"Pauling","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905211428500_keae049-B18","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3899\/jrheum.130528","article-title":"Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis","volume":"40","author":"Smith","year":"2013","journal-title":"J Rheumatol"},{"key":"2025032905211428500_keae049-B19","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/rheumatology\/kead026","article-title":"A deep learning system for quantitative assessment of microvascular abnormalities in nailfold capillary images","volume":"62","author":"Gurunath Bharathi","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905211428500_keae049-B20","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/art.40307","article-title":"Editorial: clinical Trials in Raynaud's Phenomenon: a spoonful of sugar (pill) makes the medicine do down (in flames)","volume":"69","author":"Seibold","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025032905211428500_keae049-B21","doi-asserted-by":"crossref","first-page":"152087","DOI":"10.1016\/j.semarthrit.2022.152087","article-title":"Placebo response in Raynaud's Phenomenon clinical trials: the prominent role of regression towards the mean: placebo response in Raynaud's Phenomenon","volume":"57","author":"Roustit","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025032905211428500_keae049-B22","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1111\/bph.14827","article-title":"Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone","volume":"176","author":"Larsson","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2025032905211428500_keae049-B23","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1111\/bph.13939","article-title":"Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI(2): a safer alternative to COX-2 inhibition","volume":"174","author":"Ozen","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2025032905211428500_keae049-B24","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/bph.15729","article-title":"Effects of microsomal prostaglandin E synthase-1 inhibition on resistance artery tone in patients with end stage kidney disease","volume":"179","author":"Steinmetz-Sp\u00e4h","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2025032905211428500_keae049-B25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/metabo12080721","article-title":"Prostanoid metabolites as biomarkers in human disease","volume":"12","author":"Idborg","year":"2022","journal-title":"Metabolites"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae049\/56679579\/keae049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/704\/56679579\/keae049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/704\/56679579\/keae049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:31:40Z","timestamp":1743391900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/2\/704\/7593822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,30]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae049","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,1,30]]}}}